Despite the BNT/ChAd regimen not meeting non-inferiority criteria, the SARS-CoV-2 anti-spike IgG concentrations of both heterologous schedules were higher than that of a licensed vaccine schedule (ChAd/ChAd) with proven efficacy against COVID-19 disease and hospitalisation. Along with the higher immunogenicity of ChAd/BNT compared with ChAD/ChAd, these data support flexibility in the use of heterologous prime-boost vaccination using ChAd and BNT COVID-19 vaccines.
BNT/BNT > ChAd/BNT > BNT/ChAd> ChAd/ChAd
https://www.notion.so/neranga/Covid19-Vaccines-27dd3cff7c5e48b28e4d45a225bd5a3a#b02f2b78cf994fdaa7ed4e088d10c0a0
Heterologous dosing with the adenovirus-based ChAdOx1 (AstraZeneca) vaccine followed by an mRNA vaccine induced stronger immune responses than did the homologous ChAdOx1 vaccine series, according to recent immunogenicity studies
https://drive.google.com/file/d/1oGjeVztap8h2AF8sQ_EzlSSZZDlom2Rd/view?usp=sharing